| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
Kuwanon A targets inflammatory pathways and adipocyte differentiation. It inhibits nitric oxide (NO) production with an IC50 of 10.5 μM. The compound shows significant inhibitory activity towards the differentiation of 3T3-L1 adipocytes with triglyceride (TG) inhibition values of 47.1%. It modulates cellular metabolism and suppresses oxidative stress-related damage. Kuwanon A is a natural isoflavonoid compound with anti-inflammatory and anti-adipogenic effects.
|
|---|---|
| ln Vitro |
Kuwanon A has a TG inhibition score of 47.1%, indicating strong inhibitory effect on 3T3-L1 adipocyte development. At an IC50 of 10.5 μM, Kuwanon A also significantly inhibits the generation of nitric oxide (NO) in RAW264.7 cells [1].
In vitro, Kuwanon A inhibits nitric oxide (NO) production in RAW264.7 cells with an IC50 of 10.5 μM. It shows significant inhibitory activity towards the differentiation of 3T3-L1 adipocytes with triglyceride (TG) inhibition values of 47.1%. The compound exhibits antimicrobial, anti-inflammatory, antioxidant, and anticancer effects. It modulates cellular metabolism and suppresses oxidative stress-related damage. Kuwanon A is a flavone derivative isolated from Morus alba L.. |
| ln Vivo |
In vivo, Kuwanon A has been studied for its anti-inflammatory and anti-adipogenic effects. Its ability to inhibit NO production and adipocyte differentiation suggests potential applications in inflammatory diseases and metabolic disorders. The compound's antimicrobial, antioxidant, and anticancer activities have been noted. Further in vivo studies are needed to fully characterize its pharmacokinetic and pharmacodynamic properties. The compound is typically administered orally or via injection in preclinical studies.
|
| Enzyme Assay |
In vitro enzyme assays for Kuwanon A involve measuring nitric oxide (NO) production inhibition in RAW264.7 cells. Cells are stimulated with LPS to induce NO production, and the compound is added at varying concentrations. NO levels are measured by Griess assay, and IC50 values are calculated from dose-response curves (IC50 = 10.5 μM). For adipocyte differentiation studies, 3T3-L1 cells are treated with the compound and triglyceride accumulation is measured by Oil Red O staining. Assays are performed in appropriate buffer systems with positive controls.
|
| Cell Assay |
In vitro cell-based assays for Kuwanon A are conducted in RAW264.7 macrophages and 3T3-L1 adipocytes. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with the compound at varying concentrations. NO production is measured by Griess assay. Adipocyte differentiation is assessed by Oil Red O staining and triglyceride quantification. Cell viability is assessed by MTT or CCK-8 assays. Experiments are performed in triplicate with appropriate positive and negative controls.
|
| Animal Protocol |
Kuwanon A in vivo studies are conducted in animal models of inflammation and metabolic disorders. Animals are treated with Kuwanon A via oral administration or injection. Inflammatory markers and adipocyte differentiation are assessed. For anti-inflammatory studies, animal models of inflammation such as LPS-induced endotoxemia are used. For metabolic studies, diet-induced obesity models are employed. Animals are monitored for clinical signs. Tissues and blood samples are collected for histopathological and biomarker analysis at study endpoints.
|
| ADME/Pharmacokinetics |
Kuwanon A (MW 422.47 g/mol, C25H26O6) is a prenylated flavone derivative. It is a flavone analogue isolated from the root bark of mulberry (Morus alba L.). The compound is soluble in DMSO and other organic solvents. It is stable under recommended storage conditions. Pharmacokinetic parameters such as half-life, bioavailability, and tissue distribution would be determined in species-specific studies. Kuwanon A is used in anti-inflammatory, anti-adipogenic, and anticancer research.
|
| Toxicity/Toxicokinetics |
Kuwanon A is generally well-tolerated in preclinical studies. The compound is a natural prenylated flavone from Morus alba with established safety profiles. Its anti-inflammatory, antioxidant, and anti-adipogenic activities have been demonstrated with acceptable safety profiles. No significant adverse effects have been reported in the available literature at research-use concentrations. The compound is intended for research use only. Standard safety precautions should be followed when handling. Comprehensive toxicological evaluation would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Kuwanon A belongs to the flavonoid class of compounds. It has been reported that Kuwanon A is present in Morus lhou, Morus alba, and Morus alba var. multicaulis, and relevant data are available.
Kuwanon A is a prenylated flavone derivative from Morus alba root bark that inhibits nitric oxide production (IC50 = 10.5 μM) and shows significant inhibitory activity towards 3T3-L1 adipocyte differentiation (TG inhibition 47.1%). It exhibits antimicrobial, anti-inflammatory, antioxidant, and anticancer effects. Its molecular formula is C25H26O6 with a molecular weight of 422.47 g/mol. All applications are limited to non-human research use. |
| Molecular Formula |
C25H24O6
|
|---|---|
| Molecular Weight |
420.4545
|
| Exact Mass |
420.157
|
| CAS # |
62949-77-3
|
| PubChem CID |
44258296
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
5.269
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
31
|
| Complexity |
805
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
DBUNRZUFILGKHP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H24O6/c1-13(2)5-6-16-22(29)21-19(28)11-14(26)12-20(21)30-23(16)17-7-8-18(27)15-9-10-25(3,4)31-24(15)17/h5,7-12,26-28H,6H2,1-4H3
|
| Chemical Name |
5,7-dihydroxy-2-(5-hydroxy-2,2-dimethylchromen-8-yl)-3-(3-methylbut-2-enyl)chromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3784 mL | 11.8920 mL | 23.7840 mL | |
| 5 mM | 0.4757 mL | 2.3784 mL | 4.7568 mL | |
| 10 mM | 0.2378 mL | 1.1892 mL | 2.3784 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
